Cre8ir

Cre8ir Cre8corp is a Hong Kong-Singapore based firm providing comprehensive Financial Documentation and IR

Cre8*corp sets out Cre8ir with proud, an interactive online investor relation platform in Asia. With experience of serving over 300 listed companies in Hong Kong, Cre8ir provides one-stop investor relations solution & strategy with creativity. For more infomation about our listed company clients, please visit our IR website: http://www.cre8ir.com

29/09/2026

Cre8熱烈祝賀客戶彤程新材料集團股份有限公司（股份代號：9607）成功於香港聯合交易所主板上市。Cre8對於能參與此IPO項目深感榮幸，為本項目提供一站式IPO招股書及相關文件排版、翻譯、平面設計、印刷及分發等文檔管理服務。彤程新材料集團股份有限公司是中國一家綜合性新材料供應商，主要從事新型材料的研發、生產、營銷、銷售及分銷，主要業務包括三個分部，即(i)輪胎用橡膠助劑及其他化工產品；(ii)電子材料；及(iii)可完全生物降解材料。就輪胎用橡膠助劑及其他化工產品分部而言，根據弗若斯特沙利文報告，彤程新材料集團於2025財年在全球及中國輪胎用酚醛樹脂橡膠助劑市場的銷售收入均排名第一，市場份額分別為41.4%及45.9%。在電子材料領域，於2025財年在中國半導體光刻膠市場及中國薄膜電晶體(TFT)陣列光刻膠市場的銷售收入排名中均位居本土供應商首位，市場份額分別為5.8%及26.2%。誠祝彤程新材料集團股份有限公司業務興隆！

Congratulations to our client – Red Avenue New Materials Group Co., Ltd. (Stock Code: 9607) on its successful listing on the Main Board of The Stock Exchange of Hong Kong. Cre8 is honored to be engaged in this IPO project and to provide one-stop documentation management services for typesetting, translation, graphic design, printing and distribution for the prospectus and related documents. Red Avenue New Materials Group Co., Ltd. is a comprehensive new materials provider in the PRC, primarily engaged in the R&D, production, marketing, sales and distribution of new materials, comprising three principal segments, namely (i) rubber additives for tyres and other chemical products; (ii) electronic materials; and (iii) fully biodegradable materials. With respect to rubber additives for tyres and other chemical products segment, according to the F&S Report, Red Avenue New Materials ranked first in sales revenue in both the global and PRC phenolic resins rubber additives for tyres markets in FY2025 with a market share of 41.4% and 45.9%, respectively. With respect to electronic materials, Red Avenue New Materials ranked first, in terms of sales revenue, among local suppliers in both the PRC semiconductor photoresist market and the PRC thin-film transistor (TFT) array photoresist market in FY2025 with a market share of 5.8% and 26.2%, respectively. May Red Avenue New Materials Group Co., Ltd.’s business prosper!

皓月當空，佳節思親。感謝有您同行，祝您中秋快樂，闔家幸福安康！As the bright moon shines above, we express our gratitude for walking alongside us. Wishi...
25/09/2026

皓月當空，佳節思親。感謝有您同行，祝您中秋快樂，闔家幸福安康！
As the bright moon shines above, we express our gratitude for walking alongside us. Wishing you a Happy Mid-Autumn Festival and a healthy, joyful family life.

09/07/2026

Cre8熱烈祝賀客戶普源精電科技股份有限公司（股份代號：537）成功於香港聯合交易所主板上市。Cre8對於能參與此IPO項目深感榮幸，為本項目提供一站式IPO招股書及相關文件排版、翻譯、平面設計、印刷及分發等文檔管理服務。普源精電科技股份有限公司是中國電子測量儀器公司，擁有先進的技術實力和遍佈全球的龐大版圖，專注於設計、開發、製造並交付全面電子測量儀器及解決方案，助力科學探索與行業創新。根據弗若斯特沙利文的資料，普源精電科技是中國最大的電子測量儀器供應商，按2025年收益計，全球排名第八，市場佔有率為1.2%。此外，按2025年收益計，在中國電子測量儀器市場排名第六，市場佔有率為1.9%。普源精電科技通過「RIGOL」品牌，為90多個國家及地區超過100,000名終端客戶提供服務，解決各行各業客戶在通信、新能源、半導體及教育與科研領域中的複雜測試挑戰。誠祝普源精電科技股份有限公司業務興隆！

Congratulations to our client – RIGOL Technologies Co., Ltd. (Stock Code: 537) for its successful listing on the Main Board of The Stock Exchange of Hong Kong. Cre8 is honored to be engaged in this IPO project and to provide one-stop documentation management services for typesetting, translation, graphic design, printing and distribution for the prospectus and related documents. RIGOL Technologies Co., Ltd. is an electronic test and measurement instrument company in the PRC with advanced technology capabilities and extensive global footprint, specializing in designing, developing, manufacturing and delivering a comprehensive suite of electronic test and measurement instruments and solutions that power scientific discovery and industrial innovation. According to Frost & Sullivan, RIGOL Technologies ranked eighth and are the largest PRC electronic test and measurement instrument provider globally in terms of revenue in 2025, with a market share of 1.2%. The Company also ranked sixth in the China electronic test and measurement instrument market in terms of revenue in 2025, with a market share of 1.9%. Under the “RIGOL” brand, RIGOL Technologies serve a diverse customer base of over 100,000 end customers across more than 90 countries and regions, addressing complex test challenges across communications, new energy, semiconductors, and education and research sectors. May RIGOL Technologies Co., Ltd.’s business prosper!

08/07/2026

Cre8熱烈祝賀客戶廈門瑞為信息技術股份有限公司（股份代號：7656）成功於香港聯合交易所主板上市。Cre8對於能參與此IPO項目深感榮幸，為本項目提供一站式IPO招股書及相關文件排版、翻譯、平面設計、印刷及分發等文檔管理服務。廈門瑞為信息技術股份有限公司是一家面向企業客戶提供視覺智能技術和產品的AI公司。基於自主研發的視覺大模型、深度學習相關技術、多光譜成像技術及軟硬件協同設計能力，廈門瑞為信息技術提供一系列視覺感知、視覺認知及視覺推理智能產品，並應用於民航、商業空間及安全駕駛等不同場景。根據弗若斯特沙利文的資料，按2025年的收入計，廈門瑞為信息技術在中國民航企業視覺智能產品市場排名第一，市場份額為8.7%，並在中國商業空間企業視覺智能產品市場排名第四，市場份額為1.7%。誠祝廈門瑞為信息技術股份有限公司業務興隆！

Congratulations to our client – Reconova Technologies Co., Ltd. (Stock Code: 7656) for its successful listing on the Main Board of The Stock Exchange of Hong Kong. Cre8 is honored to be engaged in this IPO project and to provide one-stop documentation management services for typesetting, translation, graphic design, printing and distribution for the prospectus and related documents. Reconova Technologies Co., Ltd. is an AI company that provides visual AI technologies and products for enterprise clients. Integrating self-developed vision large models, deep learning related technologies, multi-spectral imaging technologies, and software-hardware co-design capabilities, Reconova Technologies offers a series of visual perception, visual cognition and visual reasoning intelligence products that are applied across different scenarios, including civil aviation, commercial spaces, and driving safety. According to Frost & Sullivan, in terms of revenue in 2025, Reconova Technologies ranked first in enterprise visual AI product market for civil aviation in China, with a market share of 8.7%, and ranked fourth in enterprise visual AI product market for commercial space in China, with a market share of 1.7%. May Reconova Technologies Co., Ltd.’s business prosper!

Cre8熱烈祝賀客戶江西生物製品研究所股份有限公司（股份代號：6915）成功於香港聯合交易所主板上市。Cre8對於能參與此IPO項目深感榮幸，為本項目提供一站式IPO招股書及相關文件排版、翻譯、平面設計、印刷及分發等文檔管理服務。江西生物製...
30/06/2026

Cre8熱烈祝賀客戶江西生物製品研究所股份有限公司（股份代號：6915）成功於香港聯合交易所主板上市。Cre8對於能參與此IPO項目深感榮幸，為本項目提供一站式IPO招股書及相關文件排版、翻譯、平面設計、印刷及分發等文檔管理服務。江西生物製品研究所股份有限公司是中國最大的人用破傷風抗毒素（「人用TAT」）提供商和出口商。破傷風抗毒素是一種抗血清，通過中和破傷風梭狀芽胞菌（導致破傷風的細菌）產生的毒素，為破傷風感染提供即時保護及治療。根據弗若斯特沙利文的資料，按2025年銷量計，江西生物製品研究所是中國及全球最大的人用TAT提供商，市場份額分別為65.8%及45.8%；於中國人用TAT市場一直佔據主導地位，市場份額連續19年保持50%以上。於往績記錄期間，江西生物製品研究所的人用TAT出口至亞洲及非洲的逾30個國家和地區，佔中國出口量的近100%。按2025年的銷量計，分別是菲律賓及埃及最大的人用TAT提供商，市場份額為約90%。誠祝江西生物製品研究所股份有限公司業務興隆！

Congratulations to our client – Jiangxi Institute of Biological Products Inc. (Stock Code: 6915) for its successful listing on the Main Board of The Stock Exchange of Hong Kong. Cre8 is honored to be engaged in this IPO project and to provide one-stop documentation management services for typesetting, translation, graphic design, printing and distribution for the prospectus and related documents. Jiangxi Institute of Biological Products Inc. is the largest provider and exporter of human tetanus antitoxins (‘‘Human TAT’’) in China. Tetanus antitoxin is an antiserum that provides immediate protection and treatment against tetanus infection by neutralizing the toxin produced by Clostridium tetani, the bacterium responsible for tetanus. Jiangxi Institute of Biological Products is the largest Human TAT provider in China and globally in terms of sales volume in 2025, with a market share of 65.8% and 45.8%, respectively, according to Frost & Sullivan. Jiangxi Institute of Biological Products has consistently dominated the Human TAT market in China, maintaining a market share of above 50% for 19 consecutive years, according to Frost & Sullivan. During the Track Record Period, the Company’s Human TAT has been exported to more than 30 countries and regions in Asia and Africa, accounting for nearly 100% of China’s export volume. Jiangxi Institute of Biological Products is the largest Human TAT provider in the Philippines and Egypt, with market shares of around 90% in terms of sales volume in 2025. May Jiangxi Institute of Biological Products Inc.’s business prosper!

30/06/2026

Cre8熱烈祝賀客戶江西生物製品研究所股份有限公司（股份代號：6915）成功於香港聯合交易所主板上市。Cre8對於能參與此IPO項目深感榮幸，為本項目提供一站式IPO招股書及相關文件排版、翻譯、平面設計、印刷及分發等文檔管理服務。江西生物製品研究所股份有限公司是中國最大的人用破傷風抗毒素（「人用TAT」）提供商和出口商。破傷風抗毒素是一種抗血清，通過中和破傷風梭狀芽胞菌（導致破傷風的細菌）產生的毒素，為破傷風感染提供即時保護及治療。根據弗若斯特沙利文的資料，按2025年銷量計，江西生物製品研究所是中國及全球最大的人用TAT提供商，市場份額分別為65.8%及45.8%；於中國人用TAT市場一直佔據主導地位，市場份額連續19年保持50%以上。於往績記錄期間，江西生物製品研究所的人用TAT出口至亞洲及非洲的逾30個國家和地區，佔中國出口量的近100%。按2025年的銷量計，分別是菲律賓及埃及最大的人用TAT提供商，市場份額為約90%。誠祝江西生物製品研究所股份有限公司業務興隆！

Congratulations to our client – Jiangxi Institute of Biological Products Inc. (Stock Code: 6915) for its successful listing on the Main Board of The Stock Exchange of Hong Kong. Cre8 is honored to be engaged in this IPO project and to provide one-stop documentation management services for typesetting, translation, graphic design, printing and distribution for the prospectus and related documents. Jiangxi Institute of Biological Products Inc. is the largest provider and exporter of human tetanus antitoxins (‘‘Human TAT’’) in China. Tetanus antitoxin is an antiserum that provides immediate protection and treatment against tetanus infection by neutralizing the toxin produced by Clostridium tetani, the bacterium responsible for tetanus. Jiangxi Institute of Biological Products is the largest Human TAT provider in China and globally in terms of sales volume in 2025, with a market share of 65.8% and 45.8%, respectively, according to Frost & Sullivan. Jiangxi Institute of Biological Products has consistently dominated the Human TAT market in China, maintaining a market share of above 50% for 19 consecutive years, according to Frost & Sullivan. During the Track Record Period, the Company’s Human TAT has been exported to more than 30 countries and regions in Asia and Africa, accounting for nearly 100% of China’s export volume. Jiangxi Institute of Biological Products is the largest Human TAT provider in the Philippines and Egypt, with market shares of around 90% in terms of sales volume in 2025. May Jiangxi Institute of Biological Products Inc.’s business prosper!

Cre8熱烈祝賀客戶深圳市星源材質科技股份有限公司（股份代號：6067）成功於香港聯合交易所主板上市。Cre8對於能參與此IPO項目深感榮幸，為本項目提供一站式IPO招股書及相關文件排版、翻譯、平面設計、印刷及分發等文檔管理服務。深圳市星源...
23/06/2026

Cre8熱烈祝賀客戶深圳市星源材質科技股份有限公司（股份代號：6067）成功於香港聯合交易所主板上市。Cre8對於能參與此IPO項目深感榮幸，為本項目提供一站式IPO招股書及相關文件排版、翻譯、平面設計、印刷及分發等文檔管理服務。深圳市星源材質科技股份有限公司是一家鋰離子電池隔膜製造商，於2003年創立，在鋰離子電池隔膜的研發、生產和銷售方面累積逾20年的行業經驗。受惠於新能源汽車出貨量上升、能源存儲高速發展及其他終端使用需求攀升，中國內地電池隔膜市場近年保持穩定增長態勢。作為鋰離子電池產業的早期進入者，深圳市星源材質已發展成全球鋰離子電池隔膜市場上一家備受認可的供應商，是少數擁有獨立設備研究及設計能力的公司之一，地位獨特，並且具備專有的微孔製備技術，能夠建立具競爭力的電池隔膜生產線。深圳市星源材質在電池隔膜眾多關鍵性能指標上都表現卓越，包括厚度、孔隙率、熱收縮、透氣性和穿刺強度，憑藉專業技術和對品質的承諾，為世界領先的鋰離子電池製造商提供服務。誠祝深圳市星源材質科技股份有限公司業務興隆！

Congratulations to our client – Shenzhen Senior Technology Material Co., Ltd. (Stock Code: 6067) for its successful listing on the Main Board of The Stock Exchange of Hong Kong. Cre8 is honored to be engaged in this IPO project and to provide one-stop documentation management services for typesetting, translation, graphic design, printing and distribution for the prospectus and related documents. Shenzhen Senior Technology Material Co., Ltd. is a lithium-ion battery separator manufacturer, founded in 2003 and accumulated more than 20 years of industry experience in research and development, production and sales of lithium-ion battery separators. The battery separator market in Chinese Mainland has maintained a steady growth trend in recent years benefiting from positive impacts, such as the increasing shipment volume of new energy vehicle (NEV), rapid growth in energy storage, and other rising of end-use demand. As an early entrant in the lithium-ion battery sector, Shenzhen Senior has established itself as a recognised supplier within the global lithium-ion battery separator market. The Company’s unique position as one of the few companies with independent equipment research and design capabilities, together with the Company’s proprietary microporosity forming technology, has enabled the Company to build competitive battery separator production lines. The Company excels in many key performance indicators for battery separators, including thickness, porosity, thermal shrinkage, breathability and puncture strength. Utilising Shenzhen Senior’s technological expertise and commitment to quality, Shenzhen Senior serves world-leading lithium-ion battery manufacturers. May Shenzhen Senior Technology Material Co., Ltd.’s business prosper!

Address

1/F, China Building, 29 Queen's Road Central
Central

Telephone

+85236932600

Website

Alerts

Be the first to know and let us send you an email when Cre8ir posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Cre8ir:

Shortcuts

Share